We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
+3.03%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$38M
AUM Growth
-$194M
Cap. Flow
-$114M
Cap. Flow %
-301.07%
Top 10 Hldgs %
100%
Holding
13
New
–
Increased
–
Reduced
1
Closed
3

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$97.9M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$16M
3
AKLI
Akili Inc
AKLI
+$321K
4
RANI icon
Rani Therapeutics
RANI
+$34.3K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$11.8M 31.18%
6,724,000
– –
WVE icon
2
Wave Life Sciences
WVE
$1.17B
$11M 29.1%
1,346,892
– –
OVID icon
3
Ovid Therapeutics
OVID
$489M
$8.89M 23.42%
7,531,996
– –
STTK icon
4
Shattuck Labs
STTK
$704M
$1.8M 4.74%
515,619
– –
EQ icon
5
Equillium
EQ
$138M
$1.51M 3.99%
1,824,977
– –
XLO icon
6
Xilio Therapeutics
XLO
$59.9M
$1.16M 3.06%
105,366
– –
AMWL icon
7
American Well
AMWL
$221M
$737K 1.94%
77,733
– –
TSBX
8
DELISTED
Turnstone Biologics
TSBX
$499K 1.31%
895,824
– –
RANI icon
9
Rani Therapeutics
RANI
$87.7M
$439K 1.16%
203,190
-11,982
-6% -$34.3K
LAB icon
10
Standard BioTools
LAB
$307M
$31.9K 0.08%
16,515
– –
DNLI icon
11
Denali Therapeutics
DNLI
$3.84B
– –
-4,214,559
Closed -$97.9M
PHAT icon
12
Phathom Pharmaceuticals
PHAT
$666M
– –
-1,557,063
Closed -$16M
AKLI
13
DELISTED
Akili Inc
AKLI
– –
-738,819
Closed -$321K

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q3 2024 Portfolio in Review

As of Q3 2024, Takeda Pharmaceutical Company held 13 positions worth $38M, down 84% from $232M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Takeda Pharmaceutical Company withdrew a net $114M in Q3 2024, closing 3 positions and reducing 1 holding. Its most notable exit was Denali Therapeutics, an estimated $97.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Takeda Pharmaceutical Company's biggest Q3 2024 reduction was Rani Therapeutics, cutting an estimated $34.3K.
  • Takeda Pharmaceutical Company fully exited Denali Therapeutics in Q3 2024, selling an estimated $97.9M.
  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $38M portfolio in Q3 2024.
  • Takeda Pharmaceutical Company opened 0 new positions and closed 3 in Q3 2024.
  • Takeda Pharmaceutical Company's portfolio value fell 84% quarter-over-quarter to $38M.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2024, filed 13 Feb 2025.